Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2019 07:30 ET | Source: Arvinas Inc.

Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference

NEW HAVEN, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian...
November 21, 2019 07:30 ET | Source: Arvinas Inc.

Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that...
November 06, 2019 21:40 ET | Source: Arvinas Inc.

Arvinas, Inc. Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...
November 06, 2019 16:01 ET | Source: Arvinas Inc.

Arvinas, Inc. Announces Proposed Offering of Common Stock

NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it...
November 04, 2019 17:00 ET | Source: Arvinas Inc.

Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
October 23, 2019 06:30 ET | Source: Arvinas Inc.

Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

-Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers -Conference call...
October 17, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 TrialsNeuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein...
October 02, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new...
October 01, 2019 04:00 ET | Source: Arvinas Inc.

Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio

- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields- John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally...
August 27, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...